Please use this identifier to cite or link to this item:
Title: Nociceptin/orphanin FQ receptor ligands: pharmacological studies
Authors: Fischetti, Carmela
Supervisors: Lambert, D.
Award date: 3-Jul-2009
Presented at: University of Leicester
Abstract: The neuropeptide nociceptin/orphanin FQ (N/OFQ) selectively binds and activates the N/OFQ peptide (NOP) receptor. At the cellular level N/OFQ inhibits cAMP accumulation and Caˆ{2,+} conductance and stimulates K ˆ+ currents. N/OFQ regulates several biological functions both at central (pain, locomotion, memory, emotional responses, food intake) and peripheral (airways, cardiovascular, genitourinary and gastrointestinal systems) sites. Potent and selective NOP ligands are now required for investigating the roles played by NOP receptors in pathophysiological studies and for firmly defining the therapeutic indications of NOP receptor ligands. A novel assay to screen NOP receptor ligands has been validated with a large panel of ligands: the G\alpha_{q,I,5} chimeric protein has been used to force the NOP receptor to signal through the Ca ˆ{2,+} pathway in CHO cells. [Ca ˆ{2,+}]_i levels were monitored using the fluorometer FlexStation II. Data are in general agreement with classical Gi driven assay systems. The NOP peptide partial agonist, ZP120 was extensively characterized in vitro using electrically stimulated isolated tissues (mouse and rat vas deferens) and in vivo with the tail withdrawal assay. The selective involvement of the NOP receptor in the actions of ZP120 has been demonstrated in NOP(-/-) mice studies. A detailed pharmacological characterization of the recently identified non-peptide antagonist Compound 24 has been performed. Moreover in the context of a SAR study on Compound 24, a novel NOP ligand named Compound 35 was identified. Compound 24 and Compound 35 bound the human recombinant NOP receptor expressed in CHO_{h,N,O,P} cell membranes with high affinity (pK_i values 9.62 and 9.14, respectively). Our findings derived from functional studies on CHO_{h,N,O,P} and bioassay studies on native receptors demonstrated that Compound 24 and Compound 35 behave as potent, competitive and selective non-peptide NOP antagonists. Finally, the NOP antagonist properties of Compound 24 have been confirmed in vivo in the mouse tail withdrawal assay.
Type: Thesis
Level: Doctoral
Qualification: PhD
Appears in Collections:Theses, Dept. of Cardiovascular Sciences
Leicester Theses

Files in This Item:
File Description SizeFormat 
Carmela Fischetti PhD Thesis cd copy.pdf1.07 MBAdobe PDFView/Open

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.